Mycophenolate mofetil treatment of an H syndrome patient with a SLC29A3 mutation-Reference-Cited by-同舟云学术

Mycophenolate mofetil treatment of an H syndrome patient with a SLC29A3 mutation

Published:2020-10-26 Issue:6 Volume:33 Page:
ISSN:1396-0296
Container-title:Dermatologic Therapy
language:en
Short-container-title:Dermatologic Therapy

Author:

Behrangi Elham¹,Sadeghzadeh‐Bazargan Afsaneh¹,Khosravi Sepehr²^ORCID,Shemshadi Mahsa¹,Youssefian Leila³⁴^ORCID,Vahidnezhad Hassan³⁴^ORCID,Goodarzi Azadeh¹,Uitto Jouni³⁴^ORCID

Affiliation:

1. Department of Dermatology, School of Medicine Iran University of Medical Sciences (IUMS), Rasoul Akram Hospital Tehran Iran

2. Student Research Committee, School of Medicine, Iran University of Medical Sciences & Universal Scientific Education and Research Network (USERN) Tehran Iran

3. Department of Dermatology and Cutaneous Biology Sidney Kimmel Medical College, Thomas Jefferson University Philadelphia Pennsylvania USA

4. Jefferson Institute of Molecular Medicine Thomas Jefferson University Philadelphia Pennsylvania USA

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dth.14375

Reference14 articles.

1. Mutations in SLC29A3, Encoding an Equilibrative Nucleoside Transporter ENT3, Cause a Familial Histiocytosis Syndrome (Faisalabad Histiocytosis) and Familial Rosai-Dorfman Disease

2. A Mild Form of SLC29A3 Disorder: A Frameshift Deletion Leads to the Paradoxical Translation of an Otherwise Noncoding mRNA Splice Variant

3. The H Syndrome Is Caused by Mutations in the Nucleoside Transporter hENT3